Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. reported first quarter 2026 total revenue of $272.6 million, including $225.6 million in net product revenue and $46.8 million in royalty revenue. Management said this strong start supports raising full-year 2026 product revenue guidance.
Global Sephience sepiapterin revenue reached $125 million in the quarter, reflecting 36% quarter-over-quarter growth. The company reported a small net loss of $2.8 million, or $(0.03) per basic and diluted share, compared with a large prior-year profit that included substantial collaboration revenue.
PTC highlighted positive topline results from a 24‑month interim analysis of the PIVOT‑HD votoplam extension study and continued work on the global Phase 3 INVEST‑HD study. An open-label vatiquinone registration study is planned to start in Q3 2026. Cash, cash equivalents and marketable securities were $1.89 billion as of March 31, 2026.
PTC Therapeutics Inc. Vanguard Capital Management reports beneficial ownership of 4,284,448 shares of Common Stock, representing 5.17% of the class as reported on 03/31/2026. The filing states Vanguard has sole dispositive power over 4,284,448 shares and sole voting power over 608,192 shares. The filing explains these holdings include securities held for Vanguard funds and client accounts managed by affiliated divisions.
Vanguard Portfolio Management reports beneficial ownership of 4,871,329 shares of PTC Therapeutics common stock, representing 5.88% of the class as of 03/31/2026. The filing shows sole voting power of 66,735 shares and sole dispositive power over 4,871,329 shares. The statement clarifies holdings reflect assets managed across Vanguard affiliates and funds.
PTC Therapeutics reported positive 24‑month interim results from its PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease. Stage 2 patients showed dose‑dependent slowing of disease progression on the cUHDRS scale versus a matched natural history cohort, with 52% slowing at the 10 mg dose and 28% at 5 mg.
Safety after 24 months remained consistent with the previously favorable profile, with no treatment‑related increases in neurofilament light chain and mean levels staying below baseline, unlike typical HD progression. Novartis has initiated the global placebo‑controlled Phase 3 INVEST‑HD study of votoplam in approximately 770 early‑stage HD patients, further advancing the program.
PTC Therapeutics reported positive 24‑month interim results from its PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease. Stage 2 patients showed dose‑dependent slowing of disease progression on the cUHDRS scale versus a matched natural history cohort, with 52% slowing at the 10 mg dose and 28% at 5 mg.
Safety after 24 months remained consistent with the previously favorable profile, with no treatment‑related increases in neurofilament light chain and mean levels staying below baseline, unlike typical HD progression. Novartis has initiated the global placebo‑controlled Phase 3 INVEST‑HD study of votoplam in approximately 770 early‑stage HD patients, further advancing the program.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 2,850 shares of common stock at $70.91 per share. According to the filing, the shares were sold under an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a prior 26,000-RSU grant. After this transaction, Klein directly holds 394,070 shares, indicating a small, tax-driven reduction in his overall stake.
PTCT filed a Form 144 reporting planned or recent sales of Common Stock. The filing shows 2,850 shares tied to restricted stock vesting with an issuer compensation designation dated 04/20/2026. It also lists two dispositions in the past three months: 7,371 shares for $511,227.50 and 2,662 shares for $170,572.44. Shares outstanding are listed as 82,774,730 as of 04/21/2026.
PTC Therapeutics is holding its 2026 Annual Meeting of Stockholders virtually on June 2, 2026 at 9:00 a.m. Eastern Time via webcast at www.virtualshareholdermeeting.com/PTCT2026. Stockholders will vote on electing four Class I directors to terms ending in 2029, ratifying Ernst & Young LLP as independent auditor, and approving an advisory "say‑on‑pay" resolution for named executive officer compensation.
The record date is April 10, 2026, with 82,911,783 common shares outstanding, each entitled to one vote. The board reports that all directors except the CEO are independent, maintains a classified board structure, and emphasizes ESG, employee development, and diversity. Ernst & Young LLP billed audit and related services totaling $2.81 million in 2025, and the audit committee recommends ratification.
PTC Therapeutics executive Mark Elliott Boulding exercised stock options and sold shares in a pre-planned trade. He exercised options to acquire 2,265 shares of Common Stock at an exercise price of $39.42 per share and received 2,265 shares.
On the same date, he sold 822 shares at a weighted average price of $68.91 per share and 1,443 shares at a weighted average price of $69.75 per share, pursuant to a Rule 10b5-1 trading plan. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
PTC Therapeutics, Inc. executive Lee Scott Golden reported an automatic sale of 829 shares of Common Stock at $67.99 per share. According to the disclosure, these shares were sold pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 2,100 restricted stock units (RSUs) from an April 24, 2023 grant of 8,400 RSUs. Following this tax-related sale, Golden directly holds 79,115 shares of PTC Therapeutics common stock, so the transaction represents a small portion of his overall reported holdings.